Literature DB >> 15046457

[Mannheimia haemolytica and the pathogenesis of enzootic bronchopneumonia].

Christa Ewers1, Antina Lübke-Becker, Lothar H Wieler.   

Abstract

Mannheimia (M.) haemolytica (formerly Pasteurella [P.] haemolytica) is the primary aetiological agent of pneumonic pasteurellosis--one of the most important respiratory diseases in cattle and sheep. While bovine pneumonic pasteurellosis is regarded to be mainly caused by M. haemolytica serotype A1, and in Germany during the last years also by serotype A6, sheep can be infected by all serotypes although there is an increased prevalence of serotypes A2 and A5-7. The obligate pathogenicity of M. haemolytica is proven by isolation of pure cultures from pneumonic lungs as well as by infection studies. Knowledge about the virulence mechanisms of M. haemolytica and their molecular basis are fragmentary, most probably due to the complex gene regulation of virulence associated factors in lung tissues. This review summarizes the current literature covering virulence factors to substantiate a model of pathogenesis. After serotype A1 strains have colonized the bovine upper respiratory tract they replace other serotypes by mechanisms unknown to date. After fulminant proliferation in the upper respiratory tract the microorganisms colonize the lower respiratory tract, finally entering alveolar spaces. An inflammatory cascade is initiated by M. haemolytica LPS and Leukotoxin, causing activation of the complement system and release of cytokines. Pathognomonic for bovine pneumonic pasteurellosis is the strong influx of neutrophiles accompanied by accumulation of fibrin, finally causing necrosis of alveolar spaces. Depending on lesion size this fibronecrotizing pneumonia can result in death of the animals. In addition, possible protective antigens are discussed. There is still a great effort in the development of efficacious vaccines against pneumonic pasteurellosis in cattle and sheep caused by various M. haemolytica serotypes worldwide. The scarce knowledge concerning presence and distribution of virulence associated factors in M. haemolytica strains and their role in pathogenesis made it difficult to determine a suitable vaccine candidate in the past. In addition, there is lack of knowledge concerning the variability of virulence factors in individual isolates. Genome sequence analysis of M. haemolytica, enabling proteomics and transciptomics, hopefully will give new insight into the pathogenesis of pneumonic pasteurellosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15046457

Source DB:  PubMed          Journal:  Berl Munch Tierarztl Wochenschr        ISSN: 0005-9366            Impact factor:   0.328


  5 in total

1.  A three-way comparative genomic analysis of Mannheimia haemolytica isolates.

Authors:  Paulraj K Lawrence; Weerayuth Kittichotirat; Jason E McDermott; Roger E Bumgarner
Journal:  BMC Genomics       Date:  2010-10-04       Impact factor: 3.969

2.  Molecular study on Pasteurella multocida and Mannheimia granulomatis from Kenyan Camels (Camelus dromedarius).

Authors:  Ilona V Gluecks; Astrid Bethe; Mario Younan; Christa Ewers
Journal:  BMC Vet Res       Date:  2017-08-22       Impact factor: 2.741

3.  Molecular characterization of Mannheimia haemolytica isolates associated with pneumonic cases of sheep in selected areas of Central Ethiopia.

Authors:  Abinet Legesse; Takele Abayneh; Gezahegne Mamo; Esayas Gelaye; Liyuwork Tesfaw; Martha Yami; Alebachew Belay
Journal:  BMC Microbiol       Date:  2018-12-05       Impact factor: 3.605

4.  Channel Formation by LktA of Mannheimia (Pasteurella) haemolytica in Lipid Bilayer Membranes and Comparison of Channel Properties with Other RTX-Cytolysins.

Authors:  Roland Benz; Claudio Piselli; Andrew A Potter
Journal:  Toxins (Basel)       Date:  2019-10-17       Impact factor: 4.546

5.  Differentiated ovine tracheal epithelial cells support the colonisation of pathogenic and non-pathogenic strains of Mannheimia haemolytica.

Authors:  Nicky O'Boyle; Catherine C Berry; Robert L Davies
Journal:  Sci Rep       Date:  2020-09-11       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.